Fast-acting insulin aspart has an ultra-fast onset of exposure independent of injection region (abdomen, upper arm or thigh).

As previously observed for other mealtime insulin products, early exposure (<2 h after administration) and maximum concentration of fast-acting insulin aspart are lower for the thigh than for the abdomen and upper arm, while total exposure is comparable between all three injection regions (absolute bioavailability of ~80%).

Fast-acting insulin aspart may be administered subcutaneously in the abdomen, upper arm or thigh; however, administration in the abdomen and upper arm leads to the fastest pharmacokinetic profile.